home > news > detailed info

New Study Demonstrates: WACKER’s Antioxidant HTEssence® Lowers LDL Cholesterol Significantly

Munich/Las Vegas, September 27, 2017

At Supply Side West 2017, WACKER is presenting new results on the effect of its nature-identical hydroxytyrosol HTEssence® on heart health. A recent human clinical study demonstrates that HTEssence® is able to significantly reduce LDL (low density lipoprotein) cholesterol. Reducing LDL has been found to support heart health. Hydroxytyrosol is a highly effective antioxidant found in olives with positive effects on blood pressure, joints and the immune and cardiovascular systems. WACKER is producing the first nature-identical hydroxytyrosol free of unwanted byproducts and with a defined amount of active ingredient. HTEssence® offers an excellent price/performance ratio and is easy to process in dietary supplements and functional beverages. WACKER will be exhibiting this product at SupplySide West in Las Vegas, Nevada (USA), from September 27-29, 2017.

Hydroxytyrosol, a secondary plant metabolite, is considered a highly effective antioxidant. Reportedly, it strengthens the immune system, lowers blood pressure, reduces inflammation and improves bone and joint health. Above all, it is said to have a positive effect on blood lipid management, an effect that – according to the US National Cholesterol Education Program (NCEP) – can support a healthy heart.

A recent clinical study has now shown that WACKER’s nature-identical hydroxytyrosol HTEssence® has a positive effect on blood cholesterol. In a  randomized, double-blind, placebo-controlled crossover study, 30 healthy volunteers consumed 30 mg of hydroxytyrosol per day for a total of four weeks with two weeks washout between treatments. The hydroxytyrosol was supplemented either as HTEssence® or as olive extract in comparison to placebo.

Results show a significant reduction of LDL cholesterol in the blood plasma by 9.4 mg/dL (-8%) with HTEssence® (see Figure 1). High LDL levels are one main factor for the occurrence of coronary heart diseases and arteriosclerosis. The NCEP estimates that each one percent reduction in LDL cholesterol reduces the risk of heart disease by one to two percent (see Figure 2). Accordingly, an LDL cholesterol reduction of eight percent may reduce the risk for heart diseases by eight percent or more.

Due to its diverse modes of action, hydroxytyrosol is a popular ingredient in dietary supplements. One drawback, until recently, was the way it was produced. In nature, hydroxytyrosol is found in olives and olive leaves and its extraction is complex and cost-intensive. But with WACKER’s patented process, it is possible to synthesize a nature-identical substance of much greater purity, free of unwanted byproducts, and with a defined amount of active ingredient. Available as an odorless, water-soluble powder and liquid, the product is suitable for use in functional foods and dietary supplements, such as tablets, capsules, energy bars and functional beverages.

Further WACKER highlights at SupplySide West:

  • Dispersible curcumin and CoQ10 with high bioavailability
Cyclodextrins can considerably enhance the body’s absorption of non-bioavailable active ingredients. With the aid of gamma-cyclodextrin, curcumin’s bioavailability can be increased by a factor of around 40 compared to conventional turmeric extracts, as shown in a recent clinical study. Likewise, the bioavailability of coenzyme Q10 can be increased 18-fold by complexing it with gamma-cyclodextrin.

  • Vegan L-cystine and L-cysteine based on fermentation
The naturally occurring amino acids L-cysteine and L-cystine are often used in nutritional supplements for various functions, such as skin whitening, as an antioxidant and for stronger hair and nails. Traditionally, cysteine is extracted from human or animal sources such as hair, feathers and pig bristles using hydrochloric acid. Replacing this method with biotechnology, WACKER produces L-cystine and L-cysteine using a patented fermentation process. As a result, WACKER’s products are halal, kosher and purely vegan.

  • Alpha-cyclodextrin: a dietary fiber with a health claim
Alpha-cyclodextrin is a water-soluble source of fiber that WACKER produces enzymatically from renewable raw materials such as corn or potato starch. It is scientifically proven to regulate blood sugar after high-starch meals – an effect that has been confirmed by the European Food Safety Authority (EFSA). This makes alpha-cyclodextrin particularly suitable as a dietary supplement.

Visit WACKER at SupplySide West 2017 – Booth I133.

Figure 1: Results of a recent clinical human study show a significant reduction of LDL cholesterol with WACKER’s nature-identical hydroxytyrosol HTEssence® in comparison to olive extract and placebo (chart: Wacker Chemie AG).

Figure 2: High LDL (low density lipoprotein) levels are one main factor for the occurrence of coronary heart diseases and atherosclerosis. WACKER’s HTEssence® is able to significantly reduce LDL (chart: Wacker Chemie AG).

For further information, please contact:
Wacker Chemie AG
Media Relations & Information
Nadine Baumgartl
Tel. +49 89 6279-1604

The company in brief:
WACKER is a globally active chemical company with some 13,450 employees and annual sales of around €4.6 billion (2016, excluding Siltronic).
WACKER has a global network of 23 production sites, 19 technical competence centers and 49 sales offices.


Silicone fluids, emulsions, rubber and resins; silanes; pyrogenic silicas; thermoplastic silicone elastomers

Polyvinyl acetate and vinyl acetate co- and terpolymers in the form of dispersible polymer powders, dispersions, solid resins and solutions

Biotech products such as cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins

Polysilicon for the semiconductor and photovoltaic industries
Print this page
Send to a friend
News and Press Releases

York Health Economics Consortium offers an updated training event

Health economics evidence is a key element in much health services research and particularly in health technology assessments, including submissions for NICE single technology appraisals. Identifying economic evidence to inform submissions involves searches in a range of databases and uses a variety of strategies.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

IRT Europe Summit

10-11 April 2018, The Hotel Brussels, Belgium

New clinical trial regulations are requiring sponsors to keep tighter oversight than ever before – from audit trails to tracking system changes – resulting in high costs and trial delays. IRT Europe explores implementation best practices and how interactive response technologies can be utilised to improve supply chain planning and optimise clinical trials.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement